Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis

18 Jul 2025

Abstract excerpt

The combined use of serum and CSF biomarkers for prognostic stratification in multiple sclerosis (MS) remains underexplored. This multicenter observational study investigated associations between serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), and CSF lipid-specific IgM oligoclonal bands (LS-OCMB) with different forms of disability worsening, such as relapse-associated worsening...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Sclerosis Research Studies
Share to Neuroinflammation and Neurodegeneration Mechanisms
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40725145
DOI: 10.3390/ijms26146898

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple SclerosisPMID 40725145Read ↗

Longitudinal high-frequency blood biomarkers of axonal injury and astrocytic activation after immune reconstitution in multiple sclerosisSemantic proximity Read ↗

Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosisSemantic proximity Read ↗

Biomarkers of Progression Independent of Relapse Activity—Can We Actually Measure It Yet?Semantic proximity Read ↗

Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosisSemantic proximity Read ↗

A Predictive Autoantibody Signature in Multiple SclerosisSemantic proximity Read ↗

Proteomics profiling reveals biomarkers for predicting diagnosis, disease activity and long-term disability outcome in multiple sclerosisSemantic proximity Read ↗

Molecular mechanisms associated with multiple sclerosis progression, severity and phenotypeSemantic proximity Read ↗

Biomarker combinations from different modalities predict early disability accumulation in multiple sclerosisSemantic proximity Read ↗

Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosisSemantic proximity Read ↗

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosisSemantic proximity Read ↗

Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple SclerosisSemantic proximity Read ↗

Biomarkers of Therapeutic Response in Multiple Sclerosis: Current StatusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.